| Artículo | 2024 |
A Cross-Sectional Validation Study of Camry EH101 versus JAMAR Plus Handheld Dynamometers in Colorectal Cancer Patients and Their Correlations with Bioelectrical Impedance and Nutritional Status
|
NUTRIENTS |
| Artículo | 2024 |
Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2024 |
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC
|
Lung Cancer |
| Artículo | 2024 |
Describing differences among populations of thoracic tumors patients under and over 80 years: data analysis from the SLCG thoracic tumor registry
|
Lung Cancer |
| Artículo | 2024 |
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer
|
CLINICAL DRUG INVESTIGATION |
| Artículo | 2024 |
Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk
|
Lung Cancer |
| Artículo | 2024 |
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study
|
Lung Cancer |
| Artículo | 2024 |
HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer
|
Lung Cancer: Targets and Therapy |
| Artículo | 2024 |
Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab
|
Oncology and Therapy |
| Artículo | 2024 |
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2024 |
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
|
LANCET |
| Artículo | 2024 |
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR -Mutant Non-Small-Cell Lung Cancer
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2024 |
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2023 |
Abemaciclib, Palbociclib, and Ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer
|
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
| Artículo | 2023 |
Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer
|
CANCERS |
| Artículo | 2023 |
Avelumab in combination with cetuximab and chemotherapy as first-line treatment for patients with advanced squamous NSCLC
|
JTO Clinical and Research Reports |
| Artículo | 2023 |
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
|
Cost Effectiveness and Resource Allocation |
| Artículo | 2023 |
Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers
|
JCO PRECISION ONCOLOGY |
| Revisión | 2023 |
Current and emerging treatment options for patients with relapsed small-cell lung carcinoma: a systematic literature review
|
Clinical Lung Cancer |
| Artículo | 2023 |
Evaluation of nutritional interventions in the care plan for cancer patients: the NOA project
|
NUTRIENTS |
| Artículo | 2023 |
Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2023 |
Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in checkmate 227
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2023 |
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC lung cancer group 1613 APPLE phase II randomized clinical trial
|
ANNALS OF ONCOLOGY |
| Artículo | 2023 |
PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
|
JOURNAL OF CLINICAL MEDICINE |
| Artículo | 2023 |
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer
|
NEW ENGLAND JOURNAL OF MEDICINE |
| Artículo | 2023 |
Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study
|
Translational Lung Cancer Research |
| Artículo | 2023 |
Synergy between imputed genetic pathway and clinical information for predicting recurrence in early stage non-small cell lung cancer
|
JOURNAL OF BIOMEDICAL INFORMATICS |
| Revisión | 2023 |
Targeting the tumor microenvironment in breast cancer: prognostic and predictive significance and therapeutic opportunities
|
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
| Artículo | 2022 |
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
|
ANNALS OF ONCOLOGY |
| Artículo | 2022 |
Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
|
Oncology and Therapy |
| Artículo | 2022 |
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program
|
ONCOTARGET |
| Artículo | 2022 |
Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective
|
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH |
| Artículo | 2022 |
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
|
BMC CANCER |
| Artículo | 2022 |
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
|
JOURNAL OF THORACIC ONCOLOGY |
| Artículo | 2022 |
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
|
JOURNAL OF THORACIC ONCOLOGY |
| Revisión | 2022 |
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis
|
ESMO open |
| Artículo | 2022 |
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2022 |
PECATI: a multicentric, open-label, single-arm phase II study to evaluate the efficacy and safety of pembrolizumab and lenvatinib in pretreated B3-thymoma and thymic carcinoma patients
|
Clinical Lung Cancer |
| Artículo | 2022 |
Real-world analysis of nivolumab and atezolizumab efficacy in previously treated patients with advanced non-small cell lung cancer
|
PHARMACEUTICALS |
| Artículo | 2022 |
RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer
|
CANCER |
| Artículo | 2022 |
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
|
Breast |
| Artículo | 2022 |
SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2022 |
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
|
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| Artículo | 2021 |
Análisis de las intervenciones nutricionales en el proceso asistencial del paciente oncológico en Andalucía: el proyecto NOA
|
NUTRICION HOSPITALARIA |
| Artículo | 2021 |
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
|
Clinical and translational medicine |
| Artículo | 2021 |
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
|
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| Artículo | 2021 |
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial
|
Molecular Oncology |
| Artículo | 2021 |
Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab
|
Translational Lung Cancer Research |
| Artículo | 2021 |
Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial
|
ESMO open |
| Revisión | 2021 |
Pd-(L)1 inhibitors as monotherapy for the first-line treatment of non-small-cell lung cancer patients with high pd-l1 expression: a network meta-analysis
|
JOURNAL OF CLINICAL MEDICINE |
| Artículo | 2021 |
Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy
|
CLINICAL CANCER RESEARCH |
| Artículo | 2021 |
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
|
BMC CANCER |
| Artículo | 2021 |
Veliparib in combination with platinum-based chemotherapy for first-line treatment of advanced squamous cell lung cancer: a randomized, multicenter phase III study
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2020 |
Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study
|
JAMA Oncology |
| Artículo | 2020 |
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
|
Lung Cancer |
| Artículo | 2020 |
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
|
LANCET ONCOLOGY |
| Artículo | 2020 |
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
|
JOURNAL OF CLINICAL ONCOLOGY |
| Revisión | 2020 |
Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy
|
CANCERS |
| Artículo | 2020 |
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation
|
Cancer Epidemiology |
| Artículo | 2020 |
The roles of imprinted SLC22A18 and SLC22A18AS gene overexpression caused by promoter CPG island hypomethylation as diagnostic and prognostic biomarkers for non-small cell lung cancer patients
|
CANCERS |
| Artículo | 2019 |
Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2019 |
Clinical impact of an educational antimicrobial stewardship program associated with infectious diseases consultation targeting patients with cancer: results of a 9-year quasi-experimental study with an interrupted time-series analysis
|
JOURNAL OF INFECTION |
| Artículo | 2019 |
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance
|
Lung Cancer |
| Artículo | 2019 |
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
|
ANNALS OF ONCOLOGY |
| Revisión | 2019 |
Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer
|
CELLULAR ONCOLOGY |
| Artículo | 2019 |
Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)
|
Translational Lung Cancer Research |
| Artículo | 2019 |
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
|
NEW ENGLAND JOURNAL OF MEDICINE |
| Artículo | 2019 |
Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer
|
EUROPEAN JOURNAL OF CANCER CARE |
| Corrección | 2018 |
Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice (vol 20, pg 862, 2018)
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2018 |
Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2017 |
Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2017 |
Defining the optimal sequence for the systemic treatment of metastatic breast cancer
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Revisión | 2017 |
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Corrección | 2017 |
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions (vol 19, pg 341, 2017)
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Revisión | 2017 |
What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?
|
EUROPEAN JOURNAL OF CANCER |
| Artículo | 2016 |
Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07
|
Anticancer Research: international journal of cancer research and treatment |
| Artículo | 2016 |
Selumetinib in the treatment of non-small-cell lung cancer
|
FUTURE ONCOLOGY |
| Artículo | 2015 |
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2015 |
SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2014 |
362P ASSESSMENT OF TREATMENT RESPONSE WITH FULVESTRANT (F) 500 MG IN STANDARD CLINICAL PRACTICE THROUGH A RETROSPECTIVE STUDY: NCT01509625
|
ANNALS OF ONCOLOGY |
| Artículo | 2014 |
Bone turnover markers as predictive indicators of outcome in patients with breast and bone metastases treates with bisphosphonates: Results from a 2-year multicentre observational study (ZOMAR study).
|
BONE |
| Artículo | 2014 |
Determination of Neuronal Antibodies in Suspected and Definite Creutzfeldt-Jakob Disease
|
JAMA NEUROLOGY |
| Resumen congreso | 2013 |
Assessment of treatment response with fulvestrant (F) 500 mg in standard clinical practice through a retrospective study: NCT01509625
|
JOURNAL OF CLINICAL ONCOLOGY |
| Ponencia | 2013 |
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2013 |
Postnatal fate of the ultimobranchial remnants in the rat thyroid gland
|
JOURNAL OF MORPHOLOGY |
| Artículo | 2012 |
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|
LANCET ONCOLOGY |
| Artículo | 2012 |
Functions and workload of medical oncologists in Spain
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2012 |
Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2011 |
Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy
|
Breast Cancer Research |
| Artículo | 2011 |
Role of the Intracellular pH in the Metabolic Switch between Oxidative Phosphorylation and AerobicGlycolysis - Relevance to Cancer
|
WebmedCentral.com |
| Ponencia | 2010 |
CHRONOLOGY OF THE ARTERIAL HYPERTENSION ASSOCIATED WITH GROWTH FACTOR RECEPTOR INHIBITING TREATMENTS DERIVED FROM VASCULAR ENDOTHELIUM IN PATIENTS WITH CANCER
|
JOURNAL OF HYPERTENSION |
| Ponencia | 2010 |
Chronology of the arterial hypertension associated with inhibiting treatments of vascular endothelium growth factor receptor in patients with cancer
|
JOURNAL OF CLINICAL ONCOLOGY |
| Letter | 2010 |
The dark side of curcumin
|
INTERNATIONAL JOURNAL OF CANCER |
| Artículo | 2010 |
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)
|
ANNALS OF ONCOLOGY |
| Ponencia | 2009 |
PRIMARY BREAST SARCOMA: CLINICAL AND RETROSPECTIVE ANALYSIS OF CASES FROM JEREZ GENERAL HOSPITAL, SPAIN
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2008 |
A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Ponencia | 2008 |
Multicenter study of weekly trastuzumab, paclitaxel and carboplatin followed by a week of rest every 28 days in patients with HER2+metastatic breast cancer - incidence of central nervous system metastases
|
European Journal Of Cancer. Supplement |
| Ponencia | 2008 |
Multicenter study of weekly trastuzumab, paclitaxel, and carboplatin followed by a week of rest every 28 days in patients with HER2+ metastatic breast cancer
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2008 |
Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+metastatic breast cancer
|
CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| Ponencia | 2007 |
MULTICENTER STUDY OF WEEKLY TRASTUZUMAB, PACLITAXEL AND CARBOPLATIN FOLLOWED BY A WEEK OF REST EVERY 28 DAYS IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER (MBC).
|
JOURNAL OF CLINICAL ONCOLOGY |
| Letter | 2005 |
Bone Hodgkin lymphoma: Two patients and literature review [1]
|
REVISTA CLINICA ESPANOLA |
| Ponencia | 2005 |
DOCETAXEL FOLLOWED BY CAPECITABINE AS FIRST-LINE CHEMOTHERAPY IN METASTATIC BREAST CANCER PATIENTS: PRELIMINARY RESULTS
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2005 |
Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS).
|
Sarcoma |
| Artículo | 2004 |
TRATAMIENTO QUIMIOTERÁPICO ADYUVANTE Y NEOADYUVANTE DEL CÁNCER DE MAMA
|
Ciencia Ginecologika |
| Revisión | 2004 |
Tratamiento quimioterápico adyuvante y neoadyuvante del cáncer de mama
|
Ciencia Ginecologika |
| Artículo | 2002 |
Comparative immunohistochemical study of normal, hyperplastic and neoplastic C cells of the rat thyroid gland
|
CELL AND TISSUE RESEARCH |
| Editorial | 2002 |
Valores de los marcadores séricos tumorales en el diagnóstico precoz de las neoplasias y en los exámenes de salud a personas asintomáticas
|
REVISTA CLINICA ESPANOLA |
| Letter | 2001 |
Comment: Fluorouracil-induced aphasia: Neurotoxicity versus cerebral ischemia [4] (multiple letters)
|
ANNALS OF PHARMACOTHERAPY |
| Artículo | 2001 |
Degeneración cerebelosa paraneoplásica y carcinoma de ovario
|
Oncología |
| Letter | 2001 |
Hepatoblastoma in an adult
|
MEDICINA CLINICA |
| Letter | 2000 |
Fluorouracil-induced aphasia [1]
|
ANNALS OF PHARMACOTHERAPY |
| Letter | 1999 |
"Old" terms for "new" concepts
|
ANALES DE MEDICINA INTERNA |
| Artículo | 1999 |
Correlation between gender and spontaneous C-cell tumors in the thyroid gland of the Wistar rat
|
CELL AND TISSUE RESEARCH |
| Artículo | 1999 |
Desmoplasmatic small round cell tumor
|
Oncología |
| Letter | 1998 |
Paragangliomas: Presentation of one case and review of the diagnostic process and treatment [1]
|
Neoplasia (Spanish Edition) |
| Artículo | 1998 |
Primary non Hodgkin ovarian lymphoma associated with dermatomyositis and autoimmune anemia by cold antibodies
|
Neoplasia (Spanish Edition) |
| Artículo | 1997 |
Prospective study with dacarbacin plus alpha interferon 2b as first line therapy in metastatic melanoma
|
Neoplasia (Spanish Edition) |
| Artículo | 1997 |
Tolerance and efficacy study on alpha 2b interferon plus vinblastine in metastatic renal cell carcinoma
|
Neoplasia (Spanish Edition) |
| Artículo | 1995 |
Carcinoma de cervix de células vidriadas
|
Neoplasia (Spanish Edition) |
| Artículo | 1993 |
Metástasis a la glándula tiroides
|
Oncología |
| Artículo | 1993 |
Neuroblastoma in the adult: Three cases
|
Neoplasia (Spanish Edition) |
| Artículo | 1993 |
Tumor de Merkel: revisión de la literatura a propósito de 3 casos
|
Neoplasia (Spanish Edition) |
| Letter | 1992 |
Un caso de seis neoplasias diferentes
|
REVISTA CLINICA ESPANOLA |
